强脊方辅助治疗中轴型未分化脊柱关节病的临床观察  

Adjunctive Treatment of Axial Undifferentiated Spondyloarthritis by Qiangji Recipe:a Clinical Study

作　　者：何梦吟 范伏元[1] 

机构地区：[1]湖南中医药大学第一附属医院风湿科,长沙410007 [2]浙江省立同德医院肾病科,杭州310012

出　　处：《中国中西医结合杂志》2015年第1期37-40,共4页Chinese Journal of Integrated Traditional and Western Medicine

摘　　要：目的通过4周开放性试验评价中药强脊方辅助治疗中轴型未分化脊柱关节病的疗效和安全性。方法将符合纳入标准的54例中轴型未分化脊柱关节病肾虚督寒证患者采用随机数字表法分为2组,对照组27例,口服塞来昔布胶囊0.2 g/次,2次/天;治疗组27例,在对照组用药基础上加服强脊方(组成:仙灵脾15 g鹿角胶15 g狗脊15 g杜仲20 g续断10 g牛膝15 g骨碎补15 g桑寄生20 g虫10 g全蝎5 g独活10 g羌活10 g王不留行10 g白芥子6 g甘草6 g,每日1剂,每日2次)。疗程均为4周。两组分别于治疗前及治疗4周后对强直性脊柱炎活动指数(BASDAI)、强直性脊柱炎功能指数(BASFI)、强直性脊柱炎测量指数(BASMI)、全身痛和脊柱痛评分、患者和医生的总体评价、生活质量问卷(ASQo L)及血沉(ESR)、C反应蛋白(CRP)进行观察,并评价两组ASAS 20改善率。结果共50例患者完成了试验观察,其中治疗组26例,对照组24例。与治疗前比较,两组BASDAI、BASFI、BASMI、ASQo L、ESR、CRP均有改善,两组治疗后组间比较,除BASMI指数和ESR两项指标外,强脊方治疗组疗效均优于对照组(P<0.05,P<0.01);治疗4周后达到ASAS 20的例数治疗组为20例(76.92%),对照组为12例(50.00%),差异有统计学意义(P<0.05)。两组均无明显药物不良反应。结论强脊方联合塞来昔布胶囊治疗中轴型未分化脊柱关节病患者疗效优于单用塞来昔布胶囊者。Objective To evaluate the clinical efficacy and safety of Qiangji Recipe（ QR） in adjunctive treatment of axial undifferentiated spondyloarthritis（ axu Sp A） through a four-week open study. Methods Fifty-four axu Sp A patients of Shen-deficiency Du-channel cold syndrome（ SDDCS） in line with inclusive criteria were recruited and assigned to the treatment group and the control group according to random digit table,27 in each group. Patients in the control group took Celecoxib Capsule（ 0. 2 g each time,twice per day）. Patients in the treatment group additionally took QR（ consisting of Herba Epimedii 15 g,antler glue 15 g,Cibotium Barometz 15 g,eucommia bark 20 g,dipsacus asper 10 g,two toothed achyranthes root 15 g,drynaria 15 g,Taxillus Chinensis 20 g,ground beetle 10 g,scorpion 5 g,wild celery 10 g,notopterygium incisium 10 g,cow-fat seed 10 g,white mustard seed 6 g,and licorice root 6 g,one dose per day,twice daily）. The therapeutic course for all was 4 weeks. The Bath Ankylosing Spondylitis Disease Activity Index（ BASDAI）,the Bath Ankylosing Spondylitis Functional Index（ BASFI）,the Bath AS Metrology Index（ BASMI）,total body pain and spinal pain,patient and physician global assessment on a four-point scale,the Ankylosing Spondylitis Quality of Life（ ASQo L）,erythrocyte sedimentation rate（ ESR） and C-reactive protein（ CRP） were measured before and after 4 weeks of treatment. The primary end point in this study was the proportion of patients with a 20% improvement response according to the ASAS International Working Group Criteria（ ASAS 20 responders） at week 4. Results Totally 50 patients completed this trial,26 in the treat-ment group and 24 in the control group. Improvement of BASDAI,BASFI,BASMI,ASQo L,ESR,and CRP was shown in both groups after treatment. Better effect was shown in the treatment group in all indices except ESR and BASMI after treatment（P 〈 0. 05,P 〈 0. 01）. Twenty cases（ accounting for 76. 92%） in the treatment group achieved ASAS 20 res

关 键 词：中轴型未分化脊柱关节病 强脊方 临床观察 

分 类 号：R681.5[医药卫生—骨科学]